Magnetic Resonance Imaging in diagnostics and monitoring of treatment of multiple sclerosis patients Review article
Article Sidebar
Published:
Sep 30, 2015
Keywords:
multiple sclerosis, magnetic resonance imaging, diagnosis of MS, monitoring the MS treatment
Main Article Content
Abstract
Magnetic Resonance Imaging (MRI) is the best paraclinical tool in the diagnosis and monitoring of the treatment of multiple sclerosis (MS) patients. Constantly modified multiple sclerosis diagnostic criteria allow to establish the diagnosis and implement the treatment in a very early phase of the disease. Analysis of different magnetic resonance parameters is useful in a more complete assessment of MS therapy in both clinical trials and program sponsored by the Polish National Health Fund. This article presents the most important issues concerning diagnosis, differential diagnosis and monitoring of the treatment of MS patients based on MRI.
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Paty D.D., Oger J.J., Kastrukoff L.F. et al.: MR in diagnosis of MS; a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 1998; 38: 18-185.
2. Rovira A., Auger C., Alonso J.: Magnetic resonance monitoring of lesion evolution in multiple sclerosis. Therapeutic Advances in Neurological Disorders 2013; 6: 298-310.
3. He J., Grossman R.I., Ge Y. et al.: Enhancing patterns in multiple sclerosis: evolution and persistence. Am. J. Neuroradiol. 2001; 22: 664-669.
4. Barkhof F., Hommes O.R., Scheltens P. et al.: Quantitative MR changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991; 41: 1219-1222.
5. McDonald W.I., Compston A., Edan G. et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 2001; 50: 121-127.
6. Tintore M., Rovira M., Francis G. et al.: New diagnostic criteria for multiple sclerosis. Application in the first demyelinating episode. Neurology 2003; 60: 27-30.
7. Swanton J.K., Rovira A., Tintore M. et al.: MR criteria for multiple sclerosis in patients with clinically isolated syndrome: a multicentre retrospective study. Lancet Neurol. 2007; 6: 677-686.
8. Polman C.H., Reingold S.C., Edan G. et al.: Diagnostic criteria for multiple sclerosis: 2005 revision to the “McDonald criteria”. Ann. Neurol. 2005; 58: 840-846.
9. Agarval R., Sze G.: Neuro-Lyme disease: MR imaging findings. Radiology 2009; 253: 167-173.
10. Bester M., Petracca M., Inglese M.: Neuroimaging of multiple sclerosis, acute disseminated encephalomyelitis and other demyelinating disease. Seminars in Roentgenology 2014; 49: 76-85.
11. Wingerchuk D.M., Banwell B., Bennett J.L. et al.: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
12. Kim H., Friedmann P., Lana-Peixoto M. et al.: MR characteristic of neuromyelitis optica spectrum disorder: An international update. Neurology 2015; 84: 1165-1173.
13. Anderson V.M., Fox N.C., Miller D.H. et al.: Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J. Magn. Reson. Imaging 2006; 23: 605-618.
14. Sacco R., Bisecco A., Corbo D. et al.: Cognitive impairment and memory disorders in relapsing-remitting multiple sclerosis: the role of white matter, gray matter and hippocampus. J. Neurol. 2015; 262: 1691-1697.
15. Sormani M.P., Arnold D.L., De Stefano N.: Treatment on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann. Neurol. 2014; 75: 43-49.
16. Stangel M., Penner I.K., Kallmann B.A. et al.: Towards the implementation of‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther. Adv. Neurol. Disord. 2015; 8: 3-13.
17. Simon J.H., Li D., Traboulsee A. et al.: Standardized MR imaging protocol for multiple sclerosis: Consortium of MS centers consensus guidelines. Am. J. Neuroradiol. 2006; 27: 445-461.
2. Rovira A., Auger C., Alonso J.: Magnetic resonance monitoring of lesion evolution in multiple sclerosis. Therapeutic Advances in Neurological Disorders 2013; 6: 298-310.
3. He J., Grossman R.I., Ge Y. et al.: Enhancing patterns in multiple sclerosis: evolution and persistence. Am. J. Neuroradiol. 2001; 22: 664-669.
4. Barkhof F., Hommes O.R., Scheltens P. et al.: Quantitative MR changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991; 41: 1219-1222.
5. McDonald W.I., Compston A., Edan G. et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 2001; 50: 121-127.
6. Tintore M., Rovira M., Francis G. et al.: New diagnostic criteria for multiple sclerosis. Application in the first demyelinating episode. Neurology 2003; 60: 27-30.
7. Swanton J.K., Rovira A., Tintore M. et al.: MR criteria for multiple sclerosis in patients with clinically isolated syndrome: a multicentre retrospective study. Lancet Neurol. 2007; 6: 677-686.
8. Polman C.H., Reingold S.C., Edan G. et al.: Diagnostic criteria for multiple sclerosis: 2005 revision to the “McDonald criteria”. Ann. Neurol. 2005; 58: 840-846.
9. Agarval R., Sze G.: Neuro-Lyme disease: MR imaging findings. Radiology 2009; 253: 167-173.
10. Bester M., Petracca M., Inglese M.: Neuroimaging of multiple sclerosis, acute disseminated encephalomyelitis and other demyelinating disease. Seminars in Roentgenology 2014; 49: 76-85.
11. Wingerchuk D.M., Banwell B., Bennett J.L. et al.: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
12. Kim H., Friedmann P., Lana-Peixoto M. et al.: MR characteristic of neuromyelitis optica spectrum disorder: An international update. Neurology 2015; 84: 1165-1173.
13. Anderson V.M., Fox N.C., Miller D.H. et al.: Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J. Magn. Reson. Imaging 2006; 23: 605-618.
14. Sacco R., Bisecco A., Corbo D. et al.: Cognitive impairment and memory disorders in relapsing-remitting multiple sclerosis: the role of white matter, gray matter and hippocampus. J. Neurol. 2015; 262: 1691-1697.
15. Sormani M.P., Arnold D.L., De Stefano N.: Treatment on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann. Neurol. 2014; 75: 43-49.
16. Stangel M., Penner I.K., Kallmann B.A. et al.: Towards the implementation of‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther. Adv. Neurol. Disord. 2015; 8: 3-13.
17. Simon J.H., Li D., Traboulsee A. et al.: Standardized MR imaging protocol for multiple sclerosis: Consortium of MS centers consensus guidelines. Am. J. Neuroradiol. 2006; 27: 445-461.